Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 4/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.37 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17808307 | 0.82 | PDE3B (0.36) | PDE3BPDE3AALOX5APFEN1CYP11B2 | |
| SCHEMBL16455703 | 0.80 | UHRF1 (0.41) | ALOX5APFEN1VRK1RPS6KA3 | |
| SCHEMBL17813809 | 0.79 | POLB (0.47) | PDE3BPDE3AALOX5APFEN1CYP11B2 | |
| SCHEMBL22795814 | 0.77 | PDE3B (0.51) | PDE3BPDE3ASLC22A12 | |
| SCHEMBL16454320 | 0.77 | CYP1A2 (0.39) | PDE3BPDE3ACYP11B2CYP11B1SLC22A12 | |
| SCHEMBL16455583 | 0.77 | MAPT (0.46) | CYP11B2SLC22A12 | |
| SCHEMBL16455742 | 0.76 | CYP11B2 (0.48) | PDE3BPDE3ACYP11B2TRPA1SLC22A12 | |
| SCHEMBL25787773 | 0.75 | HPGD (0.37) | ALOX5APFEN1CYP11B2CYP11B1SLC22A12 | |
| SCHEMBL16454400 | 0.75 | KDM4E (0.46) | PDE3BPDE3A | |
| SCHEMBL16455579 | 0.75 | HSD11B1 (0.42) | PDE3BPDE3AALOX5APFEN1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611248-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2017-04-04 | — | — | US | disclosed |
| US-20160159767-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159767-A1 | CHEMICAL COMPOUNDS | DDT, CBR3, CYP1B1 | PDE3B 698/4885PDE3A 543/4885ALOX5AP 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.